Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in.

Slides:



Advertisements
Similar presentations
What a Bloody Mess! A/Professor Kent Robinson Senior Staff Specialist, Liverpool & Campbelltown Hospitals.
Advertisements

Drugs for Coagulation Disorders Andrew N. Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University October 8, 2008
Anticoagulant, Antiplatelet, and Thrombolytic Drugs
Post oral surgery bleeding for adult patients receiving antithrombotic therapy.
Vascular Pharmacology
Preventing Anticoagulation Errors with Clinical Dashboards Dan Johnson, Pharm.D., BCPS August 3, 2011.
Novel antithrombotic agents in acute coronary syndromes: better or worse than P2Y12 inhibitors Giuseppe Biondi Zoccai Sapienza Università di Roma
Principles of anticoagulant tratment
Antiplatelet Drugs (Anti-thrombotics)
1 Update on antiplatelet and anticoagulant drugs: sticky stuff KFJ Ng May 2011.
Dalia Elfawy., MD Lecturer of Anesthesia and ICU Ain Shams University 2014 RAPID REVERSAL OF ANTICOAGULATION IN TRAUMA PATIENTS.
NURS 1950 Pharmacology I 1.  Objective 1: identify general reasons anticoagulants are given 2.
Drugs used in coagulation disorders By S.Bohlooli, Ph.D.
Care of the Anti-coagulated Trauma Patient Julie Mayglothling, MD, FACEP Emergencies in Medicine March 8 th, 2012.
Anticoagulant, Antiplatelet, and Thrombolytic Drugs
ANTICOAGULANT, THROMBOLYTICS & ANTIPLATELET DRUGS.
Ticlopidine (Ticlid™) and Clopidogrel (Plavix™) Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.
Review of Anticoagulants, Thrombolytics and Anti-platelet Drugs 4 October :06 PM.
Drugs for Coagulation disorders. There are a number of different categories of drugs which modify the coagulation process: I. Anticoagulants II. Antiplatelet.
Clopidogrel 75 mg per day orally should be added to aspirin in patients with STEMI regardless of whether they undergo reperfusion.
ANTIPLATELET DRUGS.
Glycoprotein IIb/IIIa inhibitors and bivalirudin: under utilised? Azfar Zaman Freeman Hospital Newcastle-upon-Tyne.
ANTIPLATELET DRUGS Learning objectives By the end of this lecture, students should be able to: - describe different classes of anti-platelet drugs and.
Antiplatelets, Anticoagulants What are the consequences Dr Jeremy Wright Cardiologist Hearts1st, Greenslopes Private Hospital.
Antiplatelet drugs Dr.V.V.Gouripur. Antiplatelet drug An antiplatelet drug is a member of a class of drugs that decreases platelet aggregation and inhibits.
Unstable Angina and NSTEMIs: Management Principles Meira Louis Lisa Campfens.
Blood coagulation is a complex process that involves vasoconstriction, platelet clumping or aggregation, and a cascade of clotting factors produced in.
Anticoagulants, Thrombolytic Agents and Antiplatelet Drugs
Anticoagulants and reversal
Agents Affecting Blood Clotting
Anticoagulation to the max A Michael Lincoff MD Cardiologist Division of Cardiology Cleveland Clinic Cleveland, OH.
The Leeds Teaching Hospitals NHS Trust PHARMACOLOGY IN ACS OVERVIEW OF THE DATA : PRACTICAL ADVICE JIM McLENACHAN, LEEDS. 25 th January, 2007.
Coagulation Modifier Agents Lilley Pharmacology Text: Chapter 26 Original Text modified by: Anita A. Kovalsky, R.N., M.N.Ed. Professor of Nursing Original.
Jong-Yoon Yi, MD, FACC President, Heartland Education & Research Foundation.
Anticoagulants, Antiplatelets, and Thrombolytics
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
Anticoagulation in Atrial Fibrillation Dalia Hawwass PGY2 June 2015.
Drugs Used in Coagulation Disorders Presented by Dr. Sasan Zaeri PharmD, PhD.
Drugs Used in Coagulation Disorders
Adjunctive Antithrombotic for PCI Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville.
Anticoagulant, Antiplatelet, and Thrombolytic Drugs.
Introduction - Perioperative management of patients on warfarin or antiplatelet therapy involves assessing and balancing individual risks for thromboembolism.
How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy Dr. Morteza Safi Professor of interventional cardiology Cardiovascular Research.
ANTI-COAGULANT IN ICU DR.AMENA FATIMA.
Anticoagulants, Antiplatelets, and Thrombolytics
Anticoagulants, Antiplatelets, and Thrombolytics
ANTIPLATELETS AND ANTICOAGULANTS
The management of anti-thrombotics in patients undergoing GI endoscopy
Pharmacotherapy Update for STEMI: What Is New?
Regional anesthesia on anticoagulants
Robert A. Harrington, MD Professor of Medicine
Rapid Reversal of Warfarin Therapy in Patients with Intracranial / Intraspinal Bleeding Mount Auburn Hospital Blood Bank, Emergency Department, Critical.
T1: ACS Treatment Tutoring
Anticoagulants in the Treatment of Venous Thromboembolism
Anticoagulation in chronic liver disease
Anticoagulation in Atrial Fibrillation
Med Chem Tutoring for Anticoagulants, Antiplatelets, and Thrombolytics
Drugs Used in Coagulation Disorders
Anticoagulants Cooper University Hospital School of Perfusion By:
Anticoagulation Prepared by Cherie Gan.
Click here for title Click here for subtitle
Mandeep Singh, MD, MPH, Deepak L. Bhatt, MD, MPH, Gregg W
ANTICOAGULANTS Dr. A. Shyam Sundar. M.Pharm., Ph.D,
Section F: Clinical guidelines
Paul A. Gurbel, and Udaya S. Tantry JCHF 2014;2:1-14
Anticoagulant Reversal
Anti-Platelet Drugs Dr. A. Shyam Sundar. M.Pharm., Ph.D,
New oral anticoagulants and regional anaesthesia
Section B: Science update
Presentation transcript:

Anticoagulation Reversal May 11, 2013

Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in STEMI care Review the ICH treatment protocol

Patient Care Medical Knowledge Practice-Based Learning and Improvement Interpersonal and Communication Skills Professionalism Systems-Based Practice ACGME Competencies Addressed

Tissue factor pathway Contact activation pathway

Tissue factor pathway Contact activation pathway Haemophilia A Haemophilia B

What is the mechanism of action of warfarin?

What is the mechanism of action of warfarin? Inhibits Vitamin K epoxide reductase

The American College of Chest Physicians guideline for the reversal of anticoagulation therapy (8th ed.).

Vitamin K epoxide reductase

What clotting factors are affected by warfarin?

78 year old with history of PE presents with weakness and UTI. INR = 8.

58 year old with history of atrial fibrillation and HTN on warfarin presents with ICH. GCS = 6 and INR = 4.

67 year old with pmh atrial fibrillation on warfarin presents with brisk nose bleed. INR = 6.

What is the universal donor FFP type?

AB

One unit plasma replaced what percent of clotting factors?

2.5%

How low can you get the INR with FFP?

1.5

Name two problems with FFP

Time Volume

PCC What types of PCC are there?

3 factor 4 factor

3 Factor PCC Profilnine II IX X Very small amount of VII

Kcentra 4F-PCC – II – VII – IX – X

What is the mechanism of action of Xabans?

Xa inhibitor

Xabans -rivaroxaban (Xarelto)

How would you treat major bleeding in someone on Rivaroxaban?

PCC (?)

Xabans Rivaroxaban (Xarelto) Xa inhibitors PCC

Dabigatran (Pradaxa) What is mechanism of action?

dabigatran (Pradaxa)

Dabigatran (Pradaxa) Renal metabolism Can not be monitored Normal PTT helpful, but abnormal PTT not helpful PCC? FEIBA (Factor eight inhibitor bypass activity)?

What is the mechanism of action of heparin?

Heparin Activates Antithrombin III

Heparin Activates Antithrombin III

You have a patient in the ED with a non-STEMI. You put them on heparin. They develop a severe headache and you diagnose an ICH. What do you do?

How do you treat a patient with major bleeding on heparin? Protamine

LMW Heparin

Low Molecular Weight Heparin Blocks Xa Protamine causes partial reversal

Tissue Plasminogen Activator Cryoprecipitate Platelets FFP Heparin reversal if on heparin

Tissue Plasminogen Activator

Safest central line site for a patient with an elevated INR

Internal Jugular

What should the INR be before dong an LP?

 1.5

ICH Protocol

Antiplatelet Therapy Cyclooxygenase Inhibitors P2Y12 receptor antagonists (ADP) GP Iib/IIIa antagonists

How does aspirin work?

Irreversible inhibition of COX-1 (cyclooxygenase 1) Blocks TXA2 production (thromboxane A2)?

Treatment of major bleeding for a patient on aspirin?

Platelet transfusion DDAVP (analog of vasopressin)

1 unit of single donor (pheresis) platelets = how many units of pooled donors?

1 unit of single donor (pheresis) platelets = how many units of pooled donors? 6-10

What is Aggrenox?

Aspirin Dipyridamole

What is the half life of clopidogrel?

6-7 hours Binds P2Y12 receptor irreversibly

P2Y12 Inhibitors Clopidegrel (Plavix) Prasugrel Ticagrelor

What are two drug classes you may want to avoid for patients on clopidogrel?

PPIs Macrolides

Which P2Y12 inhibitor should you avoid in a patient with a history of TIA or CVA Prasugrel

How do you treat a patient on clopidogrel with major bleeding?

Platelets – 2 units DDAVP? fFVII?

GPIIbIIIa Inhibitor Abciximab (ReoPro) Triofiban (Aggrastat) Eptifibatide (Integrillin)

STEMI Protocol

What antiplatelet is given to STEMI patients at SJH and MMC?

Ticagrelor (Brilinta)

Ticagrelor "David Griffen" wrote: Frank, Could you please refresh my memory - what was the rationale regarding replacing Plavix with ticagrelor for the STEMI orders? It's proven clinical superiority in head-to-head ACS clinical trial (PLATO) for which it has received a Class I recommendation in the 2013 ACC/AHA STEMI guidelines and is preferred over plavix in the 2012 European STEMI guidelines.

What has just replaced heparin in the STEMI (Star 80) at MMC?

Angiomax (bivalirudin) Revisable inhibitor of thrombin it is a synthetic congener of the naturally occurring drug hirudin (found in the saliva of the medicinal leech Hirudo medicinalis

Anticoagulant Therapy to Support Primary PCI For patients with STEMI undergoing primary PCI, the following supportive anticoagulant regimens are recommended: UFH, with additional boluses administered as needed to maintain therapeutic activated clotting time levels, taking into account whether a GP IIb/IIIa receptor antagonist has been administered; or Bivalirudin with or without prior treatment with UFH. I IIaIIbIII I IIaIIbIII

Anticoagulant Therapy to Support Primary PCI In patients with STEMI undergoing PCI who are at high risk of bleeding, it is reasonable to use bivalirudin monotherapy in preference to the combination of UFH and a GP IIb/IIIa receptor antagonist. Fondaparinux should not be used as the sole anticoagulant to support primary PCI because of the risk of catheter thrombosis. I IIaIIbIII I IIaIIbIII Harm

Why I get confused Aggrenox Angiomax Aggrastat

Objectives Learn strategies for treating patients with iatrogenic coagulopathy Understand recent changes in STEMI care Review the ICH treatment protocol

Dr. J. Wall on coagulopathy in trauma June 6 th.

Recommended preparation CAEP 2012 Annual Conference June 3- June 6, 2012 – What's New in the Management of the Massively Bleeding Trauma Patient Dr. Sandro Rizoli